Sequenom Hires PDI to Launch and Sell Prenatal Test | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom today said that it has inked a contract with sales and marketing services firm PDI to provide the sales force that will launch and commercialize the firm's SEQureDx non-invasive prenatal genetic screening tests.

PDI will work with the Sequenom Center for Molecular Medicine, the clinical lab subsidiary of Sequenom, in supporting commercialization of the firm's Rhesus D genotyping test, its Down syndrome test, and other laboratory-developed tests. The partners will hire, train, and develop a sales team for the SCMM.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.